Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Curcumin liposomal - Signpath Pharma

Next Previous
Drug Profile

Curcumin liposomal - Signpath Pharma

Alternative Names: Diferuloylmethane; Lipocurc; Lipocurcumin; Liposomal curcumin

Latest Information Update: 20 Mar 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Signpath Pharma
  • Class Analgesics; Anti-ischaemics; Antianaemics; Antidementias; Antihistamines; Antihypertensives; Antivirals; Catechols; Chemopreventatives; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action CCR2 receptor antagonists; Chemokine CCL 5 inhibitors; Interleukin 1 inhibitors; Interleukin 6 inhibitors; Interleukin 8 inhibitors; Mast cell stabilisers; NF-kappa B inhibitors; Proto-oncogene protein c-akt inhibitors; Toll-like receptor antagonists; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Glioblastoma
  • No development reported Solid tumours

Most Recent Events

  • 01 Mar 2023 Phase-I/II clinical trials in Glioblastoma (Newly diagnosed, Combination therapy, Late-stage disease) in USA (IV) (NCT05768919)
  • 28 Sep 2022 No recent reports of development identified for phase-I development in Solid-tumours(Metastatic disease, Recurrent) in Austria (IV, Infusion)
  • 31 Oct 2019 SignPath Pharma intends to conduct further clinical trials of liposomal curcumin, in 2020

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top